Detection and measurement of hematological parameters characterizing cellular blood components

• US 20060257883A1
• Filed: 05/10/2005
• Published: 11/16/2006
• Est. Priority Date: 05/10/2005
• Status: Abandoned Application

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: Melker, Richard J., Bjoraker, David G., Dennis, Donn Michael
• Application Number:
  US11/125,937
• Publication Number:
  US 20060257883A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: G01N 33/54346 Nanoparticles
• CPC Class Codes: G01N 33/54373 involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Systems and methods for the diagnostic analysis of blood samples. The present invention uses sensor technology useful in the analysis of headspace sample from blood to provide an efficient and accurate means for identifying the presence of a volatile marker associated with hematological diseases or conditions. In a preferred embodiment, the sensor technology of the present invention includes detecting means such as RNA oligonucleotide chains or aptamers.

Claims

1. A method for detecting volatile markers associated with hematological conditions or diseases, said method comprising the steps of:

(a) collecting a sample of blood from a patient into a container, wherein said container includes a cover and provides room for a headspace sample;

(b) analyzing the headspace sample with sensor technology to determine the presence of the volatile markers associated with hematological conditions or diseases.

2. The method according to claim 1, wherein the sensor technology is based on the group consisting of polynucleotides, peptides, synthetic receptors, polymeric unnatural biopolymers, imprinted polymers, small fragments of DNA or RNA.

3. The method according to claim 2, wherein the sensor technology is based on aptamers, enzymes, antibodies, polythioureas, or polyguanidiniums.

4. The method according to claim 1, wherein the sensor technology is selected from the group consisting of surface-acoustic-wave sensors;

fluid sensor technology;

semiconductive gas sensors, mass spectrometers;

IR, V, visible and fluorescence spectrophotometers;

conductive-polymer gas-sensors;

aptamer biosensors; and

amplifying fluorescent polymer sensors.

5. The method according to claim 1, wherein the sensor technology comprises:

(a) a surface-acoustic wave (SAW) sensor capable of detecting the presence of a marker in a sample of bodily fluid, wherein the SAW sensor responds to the marker by a shift in the resonant frequency;

(b) an oscillator circuit having the SAW sensor as an active feedback element;

(c) a frequency counter in communication with said oscillator circuit to measure oscillation frequency which corresponds to resonant frequency of the SAW sensor; and

(d) a processor for comparing the oscillation frequency with a previously measured oscillation frequency of the marker and determining presence and concentration of the marker therefrom.

6. The method according to claim 1, wherein the sensor technology comprises:

(a) a sensor having an array of polymers capable of detecting the presence of the marker in the sample of bodily fluid, wherein said sensor responds to the marker by changing the resistance in each polymer resulting in a pattern change in the sensor array;

(b) a processor for receiving the change in resistance, comparing the change in resistance with a previously measured change in resistance, and identifying the presence of the marker from the pattern change and the concentration of the marker from the amplitude.

7. The method according to claim 1, wherein the volatile markers are associated with hematological conditions or diseases selected from the group consisting of:

Afibrinogenemia, Agammaglobulinemia, Anemia (i.e., aplastic anemia, hemolytic anemia, congenital nonspherocytic anemia, megaloblastic anemia, pernicious anemia, sickle cell anemia, Fanconi Anemia), Angiolymphoid Hyperplasia with Eosinophilia, Antithrombin III Deficiency, Bernard-Soulier Syndrome, Blue Rubber Bleb Nevus Syndrome, Chediak-Higashi Syndrome, Cryoglobulinemia, Disseminated Intravascular Coagulation, Eosinophilia, Erdheim-Chester Disease, Erythroblastosis, Fetal—

Evans Syndrome, Factor V Deficiency, Factor VII Deficiency, Factor X Deficiency, Factor XI Deficiency, Factor XII Deficiency, Giant Lymph Node Hyperplasia, Hemoglobinuria, Paroxysmal—

Hemoglobinuria, Paroxysmal—

Hemophilia A, Hemophilia B, Hemorrhagic Disease of Newborn, Histiocytosis, Langerhans-Cell, Non-Langerhans-Cell, Job'"'"'s Syndrome, Leukopenia, Lymphadenitis, Lymphangiomyomatosis, Lymphedema, Methemoglobinemia, Myelodysplastic Syndromes, Myelofibrosis, Myeloid Metaplasia, Myeloproliferative Disorders, Neutropenia, Paraproteinemias, Platelet Storage Pool Deficiency, Polycythemia Vera, Protein C Deficiency, Protein S Deficiency, Purpura (i.e., thrombocytopenic purpura, thrombotic thrombocytopenic purpura), Sarcoidosis, Spherocytosis, Splenic Rupture, Thalassemia, Thrombasthenia, Thrombocytopenia, Waldenstrom Macroglobulinemia, and von Willebrand Disease.

8. The method according to claim 1, further comprising the step of treating the headspace to concentrate the volatile markers in the headspace.

9. The method according to claim 8, wherein the headspace is treated to remove water vapor.

10. The method according to claim 1, further comprising the step of treating the sample of blood to concentrate the volatile markers in the headspace.

11. The method according to claim 10, wherein the sample of blood is heated to a temperature between 50°

F. to 110°

F. to promote increased concentration of volatile markers in the headspace.

12. The method according to claim 1, further comprising the step of allowing the sample of blood to equilibrate in the container.

13. The method according to claim 1, wherein the sample of blood includes materials selected from the group consisting of:

erythrocytes, hemoglobin, leukocytes, thrombocytes, plasma, sugars, lipids, vitamins, minerals, proteins, hormones, enzymes, and antibodies.

14. The method of claim 1, further comprising the step of administering a composition to a patient comprising nanoparticles, wherein each nanoparticle comprises a detector and a volatile marker, wherein detection of a target biomarker associated with a hematological condition or disease causes the release of the volatile marker for detection by the sensor technology.

15. The method of claim 14, wherein the detector is selected from the group consisting of an aptamer;

an antibody, and a protein.

16. The method of claim 14, wherein the volatile marker is selected from the group consisting of benzodiazepines;

Phenobarbitals;

dimethyl sulfoxide (DMSO), acetaldehyde, acetophenone, anise, benzaldehyde, benzyl alcohol, benzyl cinnamate, cadinene, camphene, camphor, cinnamon, garlic, citronellal, cresol, cyclohexane, eucalyptol, and eugenol, eugenyl methyl ether.

17. The method of claim 14, wherein the volatile marker is selected from GRAS compounds consisting of sodium bisulfate, dioctyl sodium sulfosuccinate, polyglycerol polyricinoleic acid, calcium casein peptone-calcium phosphate, botanicals (i.e., chrysanthemum;

licorice;

jellywort, honeysuckle;

lophatherum, mulberry leaf;

frangipani;

selfheal;

sophora flower bud), ferrous bisglycinate chelate, seaweed-derived calcium, DHASCO (docosahexaenoic acid-rich single-cell oil) and ARASCO (arachidonic acid-rich single-cell oil), fructooligosaccharide, trehalose, gamma cyclodextrin, phytosterol esters, gum arabic, potassium bisulfate, stearyl alcohol, erythritol, D-tagatose, and mycoprotein.

18. A method for non-invasive, real-time assessment of anticoagulation levels in a patient, said method comprising the steps of:

a) administering to a patient an anticoagulant;

b) administering a composition comprising nanoparticles, wherein each nanoparticle comprises a detector and a volatile marker, wherein detection of a target biomarker associated with anticoagulation levels causes the release of the volatile marker for detection by the sensor technology;

c) collecting a bodily fluid sample from the patient;

d) applying sensor technology to the bodily fluid sample to determine the presence of volatile markers associated with anticoagulation levels; and

e) determining anticoagulation levels in the patient based on the concentration of volatile markers in the bodily fluid sample.

19. The method of claim 18, wherein the anticoagulant is warfarin.

20. The method of claim 19, wherein the detector has an affinity for VKOR or a metabolite or substrate of VKOR.

21. The method of claim 18, wherein the bodily fluid sample is exhaled breath or blood.

22. The method of claim 21, wherein the sample of blood is collected in a container, wherein said container includes a cover and provides room for a headspace sample;

and wherein the sensor technology is applied to the headspace.

23. The method according to claim 18, wherein the sensor technology is selected from the group consisting of surface-acoustic-wave sensors;

fluid sensor technology;

semiconductive gas sensors, mass spectrometers;

IR, UV, visible and fluorescence spectrophotometers;

conductive-polymer gas-sensors;

aptamer biosensors; and

amplifying fluorescent polymer sensors.